Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Viatris Inc. - Common Stock (NQ: VTRS )

10.80 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
35 Generic Drugmakers Sign To Manufacture Low-Cost Version Of Pfizer's COVID Pill
Via Benzinga
7 Drug Stocks to Consider After the Viatris Plunge
As Viatris and other generic drug makers plunge, what should you buy instead? Consider these seven well-known drug stocks, all of which are good value in what's still a pricey market. 
Via InvestorPlace
AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar
Alvotech Holdings S.A. has entered into a settlement agreement with AbbVie Inc (NYSE: ABBV), allowing Alvotech to market AVT02 (100 mg/mL), its high-... 
Via Benzinga
Viatris's Return On Capital Employed Overview
Benzinga Pro data, Viatris (NASDAQ:VTRS) reported Q4 sales of $4.34 billion. Earnings fell to a loss of $263.80 million, resulting in a 184.69% decrease from last quarter.... 
Via Benzinga
Why Viatris Shares Are Trading Lower Today
Viatris Inc (NASDAQ: VTRS) is trading lower Monday after the company reported worse-than-expected top-line results for the fourth quarter and issued guidance... 
Via Benzinga
Viatris: Q4 Earnings Insights
Viatris (NASDAQ:VTRS) reported its Q4 earnings results on Monday, February 28, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2022
Upgrades Stifel upgraded the previous rating for Revolution Medicines Inc (NASDAQ:RVMD) from Hold to Buy. For the fourth quarter, Revolution Medicines had an EPS of $0.71,... 
Via Benzinga
Viatris To Pay $264M As EpiPen Antitrust Litigation Settlement: Reuters
Viatris Inc (NASDAQ: VTRS), previously known as Mylan, has agreed to pay $264 million to resolve a class-action lawsuit alleging it engaged in a scheme to delay... 
Via Benzinga
42 Stocks Moving In Monday's Mid-Day Session
Gainers Mullen Automotive, Inc. (NASDAQ: MULN) jumped 74.4% to $1.20 after the company reported progress on solid-state polymer battery pack development. Renewable Energy Group... 
Via Benzinga
67 Biggest Movers From Yesterday
Gainers Mullen Automotive, Inc. (NASDAQ: MULN) climbed 145.6% to close at $1.69 on Monday after the company reported progress on solid-state polymer battery pack... 
Via Benzinga
Mid-Morning Market Update: Markets Open Lower Amid Ongoing Russia-Ukraine Conflict
U.S. stocks opened on a downbeat note this morning, amid the ongoing Russia-Ukraine conflict, which has led to increased US sanctions on Russia. Following the market opening... 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
On Monday morning, 66 companies achieved new lows for the year. Noteable 52-Week Lows: Gilead Sciences (NASDAQ:GILD) was the largest firm on a market cap basis to set a... 
Via Benzinga
India-Based Biocon To Buy Viatris' Biosimilars Assets In $3.3B Deal
Biocon Biologics Ltd has agreed to acquire Viatris Inc's (NASDAQ: VTRS) biosimilars assets for up to $3.335 billion in stock and cash. The deal value... 
Via Benzinga
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
A Bullish Sign Appears On Viatris's Chart
If history is any guide, there may be good fortune ahead for shares of Viatris (NASDAQ:VTRS). A so-called "golden cross" has formed on its chart and, not surprisingly, this could... 
Via Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, & More
Biotech stocks managed to close the week with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid some big pharma earnings. The sector came... 
Via Talk Markets
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
14 Stocks in the Healthcare Sector
Here are 14 companies in the Healthcare Sector that have investment-grade credit ratings of BBB- or better, cash flow yield of 6% or better, future total return of at least 5%. 
Via Talk Markets
Viatris Recalls One Batch Of Diabetes Treatment Semglee Citing Missing Label Risks
Viatris Inc's (NASDAQ: VTRS) Mylan will pull one batch of non-interchangeable Semglee, also known as insulin glargine injection. The Company cited the risk of the... 
Via Benzinga
7 Pharmaceutical Stocks That Could Make You Rich
Due to expiring patents and rising competition, successful pharmaceutical stocks need to develop robust drug pipelines. 7 Pharmaceutical Stocks That Could Make You Rich 
Via InvestorPlace
7 of the Best Cheap Stocks Under $20 for 2022 to Buy Now
These cheap stocks are trading at highly attractive prices and have the potential to break through this year. 
Via InvestorPlace
10 Worst Performing S&P 500 Stocks Of 2021
The S&P 500 delivered one of its best years in recent history in 2021, gaining more than 27%. Most U.S. investors had a lot of winners in their portfolios this year, but some... 
Via Benzinga
7 of the Best Value Stocks for 2022 to Buy Now
Among the best value stocks, these seven provide both deep value and upside potential. Buy now for future gains in 2022. 
Via InvestorPlace
Jim Cramer Shares His Warning On Nio, Expresses Support For TJX And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said he doesn’t like NIO Inc. (NYSE: 
Via Benzinga
India's Biocon Mulls Merger Of Biosimilar Business With Mylan: Moneycontrol
India-based Biocon Ltd is reportedly in talks with generic drugmaker Mylan for a merger of their biosimilar businesses, financial news website ... 
Via Benzinga
The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck Gets Adcom Backing For Oral COVID-19 Antiviral Medication Molnupiravir... 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
7 Drug Stocks to Buy Now While They’re Still on Sale
Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead. 
Via InvestorPlace
Topics Supply Chain
Exposures COVID-19 Supply Chain
Biogen Loses Bid To Revive Tecfidera Drug Patent: Bloomberg
Biogen Inc (NASDAQ: BIIB) lost its appeals court bid to revive a key patent on the blockbuster multiple sclerosis drug Tecfidera, reports Bloomberg. In a related ruling... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Is It Too Late to Buy Viatris Stock?
It's not too late if you're looking for dividend income. 
Via The Motley Fool
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.